Firm’s new Niagen+ IV therapy claimed to boost NAD+ ranges larger and quicker than standard IV therapies.
Wholesome getting older bioscience firm ChromaDex has launched Niagen+, a pharmaceutical-grade intravenous and injectable type of Niagen, the corporate’s patented type of NAD+ precursor nicotinamide riboside (NR). The product might be obtainable in IV, shot and push varieties at choose clinics with a prescription beginning this summer season.
NAD+ is a coenzyme important for varied mobile processes, together with mitochondrial perform, mobile vitality manufacturing and DNA restore. Nonetheless, NAD+ ranges have a tendency to say no with age, which has pushed client curiosity in NAD+ precursors – compounds, like NR, from which our our bodies can synthesize NAD+ by way of weight loss program. ChromaDex has developed commercialized Niagen, which has develop into one of the properly studied NAD+ precursors in the marketplace.
Lately, there was a surge within the recognition of NAD+ IV therapies, intravenous remedies that administer NAD+ instantly into the physique. Nonetheless, ChromaDex claims the follow will be related to a excessive prevalence of “uncomfortable” unwanted side effects, together with complications, abdomen ache, diarrhea and nausea. The corporate is now set to launch its personal IV remedy, Niagen+, along with its established client dietary complement, Tru Niagen.
A medical trial of Niagen+ in people seems to exhibit the product’s benefits over “standard” NAD+ IV remedies. The trial outcomes, revealed as a preprint on MedRxiv, confirmed that therapy with Niagen+ IV had no opposed unwanted side effects, exhibiting superior tolerability, and with a 75% shorter infusion time in contrast with NAD+ IV.
“I’m happy that ChromaDex has developed an impeccably pure Niagen IV formulation, which is demonstrating a much less irritating expertise than NAD+ IV,” stated famend NAD+ knowledgeable Dr Charles Brenner, Chief Scientific Advisor to ChromaDex. “I’m assured that Niagen IV would be the gold customary IV materials used to check NAD+ boosting for well being situations, and I sit up for future analysis.”
Whereas not but peer-reviewed, the preprint paper additionally seems to point out that Niagen+ is simpler in elevating blood NAD+ ranges, with peaks occurring sooner and reaching larger ranges inside three hours post-infusion. ChromaDex says it plans to generate extra knowledge from bigger participant teams to “quantify and validate” its findings.
“NAD+ IV has gained recognition amongst celebrities, athletes, and longevity specialists due to the substantial advantages however the expertise will be disagreeable,” stated Rob Fried, CEO of ChromaDex. “Niagen IV is way quicker, offers superior tolerability, and importantly elevates NAD+ ranges faster and better.”
Niagen+ will initially be obtainable in restricted portions at choose clinics beginning in August, with plans for broader medical enlargement. The product will enter the booming intravenous hydration remedy market, which was valued at $1.15 billion in North America in 2022. ChromaDex estimates that the NAD+ IV market in North America is already price greater than $100 million.
“Niagen IV not solely has the potential to assist thousands and thousands seeking to assist healthspan, but in addition could present an possibility for these coping with health-related situations,” stated Dr Bal Nandra, Medical Director at IV Resolution and Ketamine Facilities of Chicago. “We’re thrilled with the medical research outcomes and sit up for future analysis as Niagen IV units a brand new customary within the NAD+ business.”
